Amlodipine | percutaneous coronary intervention, in all type of patients | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
Jorgensen (NICOLE), 2001 | amlodipine (10 mg/day) | placebo | |
| |
Diltiazem | percutaneous coronary intervention, in all type of patients | vs control | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
Corcos, 1985 | diltiazem (90 mg tid) | | |
| |
Diltiazem | | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
O’Keefe, 1991 | diltiazem (240-360 mg/day) | placebo | | Unverdorben, 1996 | diltiazem (180 mg/day) | placebo | |
| |
Nifedipine | percutaneous coronary intervention, in all type of patients | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
Whitworth, 1986 | nifedipine (10 mg qid) | placebo | |
| |
Nisoldipine | percutaneous coronary intervention, in all type of patients | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
Dens (CAPARES), 2000 | nisoldipine (40 mg/day) | placebo | |
| |
Verapamil | percutaneous coronary intervention, in all type of patients | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
Hoberg, 1994 | verapamil (240 mg bid) | placebo | |
| |